Dr Zaheer Mangera discusses the evolution of the neoadjuvant lung cancer pathway and notable changes to the TNM standards.
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 ...
Pre-Market: 4:26:27 a.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback